You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Any a and type-specific concordance b between high-risk human papillomavirus cervical DNA positivity and seropositivity, Santiago, Chile, 2001

From: Serological prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile

HPV DNA infection HPV seronegative n (%) HPV seropositive n (%) OR of seropositivity for corresponding type (95% CI)
At woman level (n = 95)    
 HR-HPV other than HPV 16 51 (72.9) 19 (27.1)  
 HPV 16 17 (68.0) 8 (32.0) 1.3 (0.5-3.4)
 HR-HPV other than HPV 18 74 (83.1) 15 (16.9)  
 HPV 18 5 (83.3) 1 (16.7) 1.0 (0.1-9.1)
 HR-HPV other than HPV 31 73 (86.9) 11 (13.1)  
 HPV 31 8 (72.7) 3 (27.3) 2.5 (0.6-10.8)
 HR-HPV other than HPV 33 84 (91.3) 8 (8.7)  
 HPV 33 2 (66.7) 1 (33.3) 5.3 (0.4-64.4)
 HR-HPV other than HPV 35 74 (80.4) 18 (19.6)  
 HPV 35 1 (33.3) 2 (66.7) 8.2 (0.7-95.8)
 HR-HPV other than HPV 45 71 (80.7) 17 (19.3)  
 HPV 45 6 (85.7) 1 (14.3) 0.7 (0.1-6.2)
 HR-HPV other than HPV 52 76 (86.4) 12 (13.6)  
 HPV 52 7 (100) 0 0
 HR-HPV other than HPV 58 79 (96.3) 3 (3.7)  
 HPV 58 12 (92.3) 1 (7.7) 2.2 (0.2-22.9)
At infection level (n = 760)    
 Positive to different HR-HPV 582 (85.0) 103 (15.0)  
 Positive to same HR-HPV 58 (77.3) 17 (22.7) 1.7 (1.1-2.5)
  1. aAny HPV refers to HPV types 16, 18, 31, 33, 35, 45, 52, and 58.
  2. bOnly among HPV DNA positive infections.
  3. Bold: statistically significant results (p-value < 0.05).
  4. HR: high-risk, HPV: human papillomavirus, OR: odds ratio, CI: confidence interval.